1649470-12-1

Basic information

• Product Name: tert-butyl 6-chloro-2,3-dihydro-1H-pyrrolo[3,2-c]pyridine-1-carboxylate
• CAS NO: 1649470-12-1
• Molecular Weight: 254.716
• Mol File: 1649470-12-1.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: tert-butyl 6-chloro-2,3-dihydro-1H-pyrrolo[3,2-c]pyridine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 6-chloro-2,3-dihydro-1H-pyrrolo[3,2-c]pyridine-1-carboxylate(1649470-12-1)
• EPA Substance Registry System: tert-butyl 6-chloro-2,3-dihydro-1H-pyrrolo[3,2-c]pyridine-1-carboxylate(1649470-12-1)

Safety Data

• Hazardous Substances Data: 1649470-12-1(Hazardous Substances Data)

Upstream product

• 74976-31-1 6-chloro-1H-pyrrolo[3,2-c]pyridine 
• 800402-12-4 2-chloro-4-amino-5-iodopyridine 
• 14432-12-3 4-Amino-2-chloropyridine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 23596-25-0 6-chloro-2,3-dihydro-1H-pyrrolo[3,2-c]pyridine 

Relevant articles and documents

ROCK KINASE INHIBITORS

The present invention relates to compounds that inhibit ROCK activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of inhibiting ROCK activity and methods for treating, for example cerebral cavernous malformation syndrome (CCM) and cardiovascular diseases using the compounds and pharmaceutical compositions of the present invention.

HETEROCYCLIC COMPOUND

The present invention provides an agent for the prophylaxis or treatment of autoimmune diseases (e.g., psoriasis, rheumatoid arthritis, inflammatory bowel disease, Sjogren's syndrome, Behcet's disease, multiple sclerosis, systemic lupus erythematosus etc.) and the like, which has a superior Tyk2 inhibitory action. The present invention relates to a compound represented by the formula wherein each symbol is as defined in the specification, or a salt thereof.